Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Operations (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of Cash from Operations readings, the most recent being 1328711.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations fell 2266.61% to 1328711.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 7433723.0, a 52.47% decrease, with the full-year FY2025 number at 2837272.0, up 74.23% from a year prior.
  • Cash from Operations hit 1328711.0 in Q1 2026 for Neuroone Medical Technologies, up from 3115835.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1017817.0 in Q3 2022 to a low of 3809391.0 in Q4 2023.
  • Median Cash from Operations over the past 5 years was 2636624.0 (2022), compared with a mean of 2118878.24.
  • Biggest five-year swings in Cash from Operations: skyrocketed 150.16% in 2022 and later crashed 2266.61% in 2026.
  • Neuroone Medical Technologies' Cash from Operations stood at 3492253.0 in 2022, then dropped by 9.08% to 3809391.0 in 2023, then skyrocketed by 105.46% to 208049.0 in 2024, then tumbled by 1597.64% to 3115835.0 in 2025, then soared by 57.36% to 1328711.0 in 2026.
  • The last three reported values for Cash from Operations were 1328711.0 (Q1 2026), 3115835.0 (Q4 2025), and 1525672.0 (Q3 2025) per Business Quant data.